Summary
Cellogen Therapeutics, founded in 2021, is developing CAR-T cell therapies for blood cancers and gene therapies for inherited blood disorders in India, aiming to make these treatments more accessible. The company has secured approximately $2 million from Natco Pharma and ₹20 crore from Kotak Alternate Asset Managers to advance its clinical programs and expand its pipeline.